Brief: Fractyl Health Receives FDA IDE Approval For The Revita® Remain-1 Pivotal Study Of Weight Maintenance In Obesity After Discontinuation Of Glp-1 Based Drugs
01/04/2024 12:09
April 1 (Reuters) - Fractyl Health Inc GUTS.O :
* FRACTYL HEALTH RECEIVES FDA IDE APPROVAL FOR THE REVITA®
REMAIN-1 PIVOTAL STUDY OF WEIGHT MAINTENANCE IN OBESITY AFTER
DISCONTINUATION OF GLP-1 BASED DRUGS
* FRACTYL HEALTH INC: WILL INITIATE REMAIN-1 RANDOMIZED,
DOUBLE
BLIND PIVOTAL STUDY AND BEGIN PROVIDING UPDATES ON OPEN LABEL
COHORT IN H2 2024
Source text for Eikon: ID:nGNXqcSSG
Further company coverage: GUTS.O
((Reuters.Briefs@thomsonreuters.com;))